Abstract: While immune checkpoint inhibitors (ICIs) confer significant survival benefits in patients with cancer, drug-related myocarditis, a fatal complication, has become a new clinical challenge. This consensus statement summarizes the data on the epidemiology, pathological characteristics, clinical features, diagnosis and differential diagnosis, clinical classification, and treatment of ICI-related myocarditis, with a special focus on proactive monitoring strategies for detecting early myocardial injury. This consensus provides guidance and suggestions for the surveillance and management of ICI-related myocarditis.